© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
The mechanism of action of trastuzumab (Herceptin), a monoclonal antibody that is approved for the treatment of early-stage breast cancer that is HER2-positive.
Trastuzumab (Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Herceptin is approved for the treatment of early-stage breast cancer that isHumanEpidermal growth factorReceptor2